Pharma Commercialization: A Deep Dive in Market Access

The increasing complexity of novel therapeutics has created a tailwind for pharmaceutical research and development spend, buoying the number of novel drug approvals and increasing the demand for sophisticated, outsourced commercialization capabilities. In this white paper, we take an in-depth look at market access in the United States, one of the most sought-after subsegments of pharma commercialization. We’ll focus on why market access is increasingly important across all stages of the drug development lifecycle, what affects drug pricing and reimbursement decisions, the impact of the Inflation Reduction Act, and other recent trends across the segment.

Houlihan Lokey is a global M&A market leader with dedicated coverage within the pharma commercialization sector, giving us a unique vantage point into key trends across the industry. We are happy to share the insights we’ve garnered from 22 closed commercialization deals since 2019, and we hope this white paper will provide you with a helpful perspective on market access.